ipilimumab,nivolumab,durvalumab,vinorelbine,paclitaxel,carboplatin,cisplatin,gemcitabine,docetaxel,pemetrexed
bms,astrazeneca
['durva', 'aegean']
 it's too early to see if the adjuvant durva contributes - the benefit (if there is one) would probably be reflected in 2y+ efs rate and os. if you believe that some (sub-pcr) will benefit from more io - that 4 doses is not enough - aegean allows you the option of giving more.
Director of Thoracic Oncology & Developmental Therapeutics @LombardiCancer, Associate Professor @Georgetown, Co-Host Official @IASLC Podcast #ITYSL #HereWeGo